Explore Our Pipeline
HealZen is committed to bringing first-in-class or differentiated therapies to patients without effective treatment options. Starting from small molecule inhibitors, now we are much more focusing on Target Protein Degradation (TPD) and Degrader Antibody Conjugate (DAC) as the new therapeutic approaches for cancer and other major diseases.
Drug Program
Target
Modality
Indication
Discovery
IND-enabling
Phase l
Phase ll
Phase lll
HZ-H08905
CK1ε & PI3Kδ
Inhibitor
PTCL
HZ-A-018
BTK
Inhibitor
PCNSL
HZ-Q1070
BTK
Degrader
Hematology
Autoimmune
HZ-L105
Bcl-2
Inhibitor
Hematology
HZ-S
HPK1
Degrader
Cancer
Undisclosed
Undisclosed
Degrader
Cancer
Partnerships
We are working both on our own and with strategic partners, including local leading pharmas, academic Institutes, and others, to broaden and further accelerate our pipeline programs.
We are ready to discuss a variety of different collaboration possibilities across our TPD and DAC platforms and all programs in the pipeline.
Modality
Indication
PCC
Clinical Stage
Approved
Model
Partners
Agonist
CNS
License out
Inhibitor
Autoimmune
License out
BTK
Degrader
Hematology
License out
Inhibitor
HCV
License out
HealZen Therapeutics Co., Ltd.
Telephone: +86-571-86933001
E-mail: info@healzentx.com
Address: 8th Floor, Building 16, Hexiang Science and Technology Center, Qiantang District, Hangzhou City, P.R.China
Copyright © HealZen Therapeutics Co., Ltd. Powered by www.300.cn